Paraganglioma: Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Paragangliomas are rare neuroendocrine tumors arising from extraadrenal chromaffin cells (paraganglia) distributed along the sympathetic and parasympathetic nervous chains from the skull base to the pelvic floor. They are closely related to pheochromocytomas (adrenal medullary tumors) and share genetic, biochemical, and molecular features. Incidence is approximately 2-8 cases per million population per year. Head and neck paragangliomas (glomus tumors) — arising from parasympathetic paraganglia at the carotid body, jugulotympanic region, and vagal body — are characteristically non-functional (no catecholamine secretion) and present as slowly enlarging masses causing local compressive symptoms. Sympathetic paragangliomas of the thorax, abdomen, and pelvis are more frequently functional (catecholamine-secreting) and may cause hypertensive symptoms. Malignancy (defined by metastatic spread) occurs in approximately 15-20% of abdominal sympathetic paragangliomas and is strongly associated with SDHB germline mutations.

Paragangliomas have the highest rate of hereditary predisposition of any human neoplasm — approximately 35-40% of cases arise in the context of a germline mutation. The succinate dehydrogenase (SDH) subunit genes are the most commonly mutated: SDHD mutations predispose to multiple head and neck paragangliomas; SDHB mutations are most strongly associated with malignant/metastatic paraganglioma (30-50% malignancy risk); SDHC mutations cause primarily head and neck tumors; and SDHA mutations cause broader pheochromocytoma-paraganglioma syndrome. Additional hereditary associations include VHL syndrome (von Hippel-Lindau, VHL gene mutation), MEN2 syndrome (RET mutations), and neurofibromatosis type 1 (NF1 gene). Somatic HIF2A (EPAS1) gain-of-function mutations are the most common cause of sporadic polycythemia-paraganglioma-somatostatinoma syndrome. Comprehensive germline genetic testing encompassing all SDH subunit genes plus VHL, RET, MAX, TMEM127, FH, and NF1 is essential for all patients.

The clinical presentation differs markedly between functional sympathetic and non-functional parasympathetic paragangliomas. Functional tumors secrete catecholamines (norepinephrine predominantly, with variable epinephrine and dopamine), causing paroxysmal or sustained hypertension, episodic severe headache, diaphoresis (profuse sweating), and palpitations — the classic catecholamine triad. Additional manifestations include pallor, anxiety, tremor, hyperglycemia, and weight loss. Hypertensive crises can be precipitated by palpation of the tumor, anesthesia, surgical manipulation, and certain medications (metoclopramide, tricyclic antidepressants, glucagon, and opioids). Head and neck paragangliomas typically present as a painless pulsatile neck mass with or without pulsatile tinnitus; involvement of adjacent cranial nerves (IX, X, XI, XII) causes hoarseness, dysphagia, or tongue weakness. Many abdominal paragangliomas are now discovered incidentally on cross-sectional imaging performed for unrelated reasons.

Biochemical evaluation of catecholamine excess uses plasma fractionated free metanephrines or 24-hour urine fractionated catecholamines and metanephrines — plasma free metanephrines have the highest sensitivity (greater than 97%) for functional tumors. Anatomic imaging with CT or MRI localizes the primary tumor. Functional imaging with 68Ga-DOTATATE PET/CT is currently the most sensitive modality for staging and detection of metastatic or multifocal disease; it identifies somatostatin receptor expression essential for PRRT eligibility. 123I-MIBG scintigraphy or 18F-FDOPA PET are alternatives for MIBG-avid tumors relevant to 131I-MIBG therapy selection. Comprehensive germline SDH gene panel testing (SDHB, SDHC, SDHD, SDHA) plus VHL, RET, NF1, MAX, TMEM127, and FH is mandatory for all patients with paraganglioma regardless of age or family history.

Surgical resection is the primary treatment for localized paraganglioma, offering the only chance of cure. For functional tumors, preoperative medical preparation with alpha-adrenergic blockade using phenoxybenzamine (10-14 days) is mandatory to prevent life-threatening intraoperative hemodynamic instability. Beta-blockade may be added after adequate alpha-blockade has been achieved to control reflex tachycardia. High-volume endocrine surgical centers achieve superior outcomes for complex skull base or vascular tumors. For metastatic or unresectable disease, 177Lu-DOTATATE PRRT is preferred for DOTATATE-avid tumors, achieving disease stabilization or objective response in a significant proportion of patients. 131I-MIBG therapy (including high-activity Azedra formulation) is used for MIBG-avid metastatic disease. Systemic agents including cabozantinib, sunitinib, and temozolomide-based regimens are used for tumors not amenable to PRRT or MIBG therapy. External beam radiotherapy controls symptomatic bone or skull base metastases.

No primary preventive measures exist for paraganglioma. However, identifying hereditary disease through germline genetic testing enables surveillance of at-risk family members and can lead to earlier tumor detection at a curable stage. First-degree relatives of patients with confirmed SDH, VHL, RET, or NF1 mutations should receive genetic counseling and, if mutation-positive, enter structured surveillance programs with periodic plasma metanephrines and imaging. Germline SDHB or SDHD mutation carriers should undergo plasma or urine metanephrine testing and 68Ga-DOTATATE PET or whole-body MRI every 2 years, starting at age 10 or earlier. Avoiding unnecessary medications that can trigger catecholamine release (metoclopramide, glucagon, certain anesthetic agents) is important in patients with unresected functional tumors. Surgical cure of a primary tumor reduces but does not eliminate long-term recurrence risk; lifelong surveillance is essential for all patients.

Any patient with episodic severe headache, profuse sweating, and palpitations — especially when accompanied by sustained or paroxysmal hypertension — should be evaluated by an endocrinologist for pheochromocytoma or paraganglioma. These symptoms may be triggered by changes in posture, physical exertion, or specific foods, and are often initially attributed to anxiety or panic disorder. A pulsatile neck mass, particularly if it is located near the carotid bifurcation or behind the ear, should be evaluated by an ENT or vascular surgeon with consideration of paraganglioma. Anyone with a family history of paraganglioma, pheochromocytoma, or a known SDH/VHL/MEN2 syndrome mutation should be proactively evaluated by an endocrinologist even without symptoms. Patients who are found incidentally to have a retroperitoneal or thoracic mass on imaging should include paraganglioma in the differential and have plasma metanephrines measured before any biopsy or surgical procedure.

Benign localized paragangliomas have excellent outcomes after complete surgical resection; long-term surveillance remains essential due to late recurrence risk. Malignant paraganglioma (defined by metastases) with SDHB mutation: 5-year survival approximately 36-60%, varying with disease extent and tumor DOTATATE/MIBG avidity. All patients require lifelong surveillance with annual or biennial biochemical testing and periodic imaging. The prognosis for Paraganglioma: Causes, Symptoms, Diagnosis and Treatment varies depending on severity at diagnosis, the patient's overall health, and how promptly treatment is initiated. With early diagnosis and appropriate management, many patients achieve good outcomes and maintain quality of life. Regular follow-up with healthcare providers is essential to monitor progress, adjust treatment as needed, and detect any complications early. Adherence to prescribed treatments and lifestyle modifications significantly improves long-term prognosis.